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ABSTRACT
Introduction: The clinical importance of hu-
moral-mediated acute rejection has been pro-
gressively recognised. Early recognition and
treatment with plasmapheresis and intravenous
immunoglobulin have recently improved short
term prognosis.
Case report: In this report we describe the
clinical features of three 2nd transplant patients
developing severe acute humoral rejection dur-
ing the first week post-transplant while on anti-
Triple regimen with rituximab,
plasmapheresis and intravenous
immunoglobulin in the treatment of dialysis
dependent acute humoral-mediated rejection
in kidney grafts
Pedro Pessegueiro1, Fernando Nolasco2,3, Sandra Sampaio4, Fernanda Carvalho3
Felicidade Manuel2,3, Engrácia Barber2,3, Helena Viana2,3, João Sousa2,3,
Marília Possante2,3, Margarida Domingos2,3, José Reimão Pinto2,3,
João Ribeiro Santos2,3, Eduardo Barroso2
1 Unidade de Nefrologia, Hospital Espírito Santo, Évora
2 Unidade de Transplante, Hospital Curry Cabral, Lisboa
3 Serviço de Nefrologia, Hospital Curry Cabral, Lisboa
4 Serviço de Nefrologia, Hospital Distrital de Faro, Faro
Case Report
Received for publication: 16/09/2005
Accepted in revised form: 07/02/2006
thymocyte globulin therapy. Treatment with plas-
mapheresis/intravenous immunoglobulin/
rituximab resulted in rapid reversal of oliguria,
and recovery of renal function within the 1st week
of treatment in 2/3 patients. Diagnosis was con-
firmed by graft biopsies revealing peritubular
neutrophiles and C4d deposits.
Sequential graft biopsies in all three patients
revealed complete histological recovery within
two weeks. One patient never recovered renal
function, and one patient lost his graft at three
months following hemorrhagic shock. After 2
years follow up, the remaining patient maintains
a serum creatinine of 1.1mg/dl.
Conclusion: The regimen using plasmaphe-
resis plus intravenous immunoglobulin and
rituximab was effective in rapidly reversing se-
vere acute humoral rejection.
Key-Words: Acute humoral-mediated rejection;
kidney transplant; plasmapheresis; rituximab.
INTRODUCTION
The importance and clinical significance of
humoral alloimmunity in renal transplant (Tx) is
currently under re-evaluation.
Acute humoral rejection (AHR) seems more
prevalent than previously thought, with a preva-
lence of 5% to 7%, increasing to 20-30% in cases
of biopsy performed for acute rejection1.
The criteria for diagnosis of AHR have recently
been established2,3: 1) evidence of clinical graft
disfunction, 2) histologic evidence of tissue in-
jury (neutrophil margination in the peritubular
capillaries, acute tubular injury, fibrinoid necro-
sis), 3) immunopathological evidence for anti-
body (C4d positive staining in the peritubullar
capilaries or Ig/C3 deposition in arteries) 4) and
serological evidence of anti-donor antibodies at
time of biopsy.
Prognosis for AHR varies, depending on the
severity of clinical/histological lesions, and timing
of treatment.
In this report we describe the prompt reco-
very of two out of three patients with severe AHR,
developed under treatment with anti-thymocyte
gobulin (ATG)/tacrolimus/micophenolate mofetil,
and rapidly recovering after treatment with plas-
mapheresis (PMF), intravenous immunoglobu-
lin (IVIG) and rituximab.
CASE REPORT
The authors describe the clinical features of
three kidney transplanted patients all receiving
a 2nd kidney graft developing severe AHR (Table
I). All were presensitized patients, two with >75%
panel-reactive antibodies. Protocol induction
therapy included ATG (2mg/kg/day; 10 days),
tacrolimus (0.07mg/Kg/day increasing to 0.2mg/
Kg/day by 7th day) plus mycophenolate mophetil
(MMF; 500mg/day increasing to 2g/day) plus
prednisolone (20mg/day).
Patient A received his second renal transplant
from a cadaver donor (20% glomerular sclero-
sis on the donor kidney biopsy), and had a pre-Tx
weakly positive HLA-II cytometric flux crossmatch
(FCC), unknown at the time of transplant. He was
anuric and required haemodialysis.
Patient B received a second kidney allograft
from a cadaver donor, and although presenting
a pre-Tx negative FCC he had a historical posi-
tive control (Table II). After Tx, a rapid recovery
of renal function was attained, with serum crea-
tinine reaching 2.0 mg/dl at the 5th day. 48 hours
after, low grade fever, rapid decrease in diuresis
and renal function were observed, leading to ur-
gent haemodialysis.
Patient C, hepatitis C virus positive, received
his second kidney transplant from a cadaver
donor (presenting an anatomical abnormality:
two small renal arteries). Although pre-Tx
citotoxic crossmatch was negative, FCC turned
out slightly positive (Table II). After an initial slight
recovery of renal function until the 4th day post-
Tx., low grade fever appeared, and a rapid de-
crease in urinary output occurred which lead to
induction of dialysis at the 7th day.
Blood cultures returned negative and allograft
ecodoppler was normal in all three patients.
All three patients underwent graft biopsy and
this showed the presence of neutrophiles in the
peritubular capillaries and a imunofluorescence
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C4d positive result. Severe AHR was diagnosed
(Figure 1).
All patients were treated with 5 daily PMF
sessions (one plasma volume exchange), IVIG
(400mg/kg) after each PMF, repeated once af-
ter 21 days, plus one or two (21 days apart) ad-
ministrations of rituximab (375 mg/m2).
Three days after initiating this regimen, 2/3
patients presented a rapid increase in diuresis,
with a steady recovery of renal function (patient A:
creatinine 1.9mg/dl at day 50; patient B: creati-
nine 1.1mg/dl at day 90). Patient C remained
anuric, dialysis-dependent.
Post-treatment graft biopsies showed a com-
plete resolution of the AHR features in all pa-
tients. However, patient A still showed donor
severe chronic lesions and patient C showed
presence of ischemic glomeruli.
Although all patients attained resolution of the
AHR, two of them lost permanently their graft
function. Patient A, while partly recovering renal
function (minimal serum creatinine of 1.9mg/dl
even after an episode of acute celular rejection
BANF IA), eventually had his graft removed as a
consequence of multiple surgical complications
(infected volumous linfocele, life-threatening
haemorrhage after a graft biopsy). Patient C
continued to show ischemic glomerular lesions,
and further investigation revealed a high pres-
sure arteriovenous shunt as the cause of de-
creased diastolic blood flow. Even after AV shunt
removal, no renal recovery was observed.
In conclusion, the treatment regimen used
allowed 100% resolution of severe AHR and al-
though only 33% of graft survival was attained,
no graft loss was directly caused by humoral
rejection, but by haemodynamic complications.
Moreover, all patients saw their initial histologi-
cal abnormalities completely resolved.
During follow up of the remaining patient (B)
with functioning allograft, a cutaneous-born sys-
temic infection by Alternaria spp fungus was dia-
gnosed. It was  treated with long term anti-my-
cotic therapy. No other severe complication was
Table I - Patient’s outlined characteristics
* Rejection occurred at 3 months after transplant; A/G/R: age/gender (Male, Fe-
male)/race (Caucasian, Black); CRF: chronic renal failure; IgAN: Immunoglobulin
A nephropathy; HNAS: Hypertensive nephroangiosclerosis; Tx: transplant
Acute hummoral mediated rejection. Presence of neutrophiles in
the peritubular capillaries (arrows) and pericapillaries
imunofluorescence C4d positive stain. Acute tubular necrosis
also observed. IMF: immunofluorescence; H&E: hematoxylin
and eosin staining.
Table II - Crossmatch and panel-reactive antibodies monitoring
features
Tx: transplant; Tr: treatment; FCC: flux citometry crossmatch; PRA: panel-reac-
tive antibodies; PCr: plasma creatinine; I: HLA antigens class I (normal values
<200UI); II: HLA antigens class II (normal values <250UI)
Figure 1
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noticed, allowing, after 24 months, a plasma cre-
atinine level of 1.1mg/dl (Table II).
DISCUSSION
Over the last 40 years, most clinical and re-
search emphasis has been on the cellular as-
pects of allograft rejection. It is only recently that
there has been more emphasis on the antibody-
mediated injury, due to the development of a new
diagnostic technique, C4d staining4,5. This
showed that AHR is more prevalent than previ-
ously considered6, and that these patients seem
to have worse prognosis, with an increased rate
of early graft loss and an early and increased
progression to chronic graft dysfunction7-10.
Crespo et al1 have shown that the presence
of C4d correlates very well with the presence of
anti-donor specific antibodies in the serum.
These anti-HLA antibodies can be rather non
specific, being directed mostly against class I1.
The antibodies are mainly IgG, produced by
plasma cells. These cells represent the goal in
terms of inhibiting antibody production.
Controversy stills reigns over how best to treat
these patients. Several therapies have been tried,
but all with limited success, mainly due to their
inability to inhibit the antibody-producers plasma
cells1,11-16. The therapies currently available are
MMF, IVIG, rituximab, and removal of antibodies
by PMF.
Mycophenolate acts by inhibiting B cell proli-
feration, mostly by reducing expression of mo-
lecules responsible for B cell activation and sur-
vival. It therefore inhibits de novo immune
responses, having a negligible effect in terms of
inhibiting antibodies that already exist.
IVIG is effective in reducing anti-HLA antibo-
dies in sensitized patients12. It is also effective
in treating mild AHR12,17. However, it is expen-
sive, has significant side effects, and is non-spe-
cific. IVIG efficacy appears to be mainly due to
mechanisms such as an anti-idiotypic antibody
effect and inhibition of the B cell activation12,17.
Rituximab is a chimeric antibody directed
against CD20, which is only expressed on rest-
ing and activated B cells, not on plasma cells.
With the isolated use of this drug, antibody pro-
duction by plasma cells is maintained, but a de-
crease in de novo antibody production occurs
and, by clearing B cells, it also clears B cells
antigen-presenting function. Its role seems li-
mited to maintaining a low level of production of
donor antibodies after gross removal has been
attained, suggesting a possible role in prevent-
ing further AHR episodes.
The triple therapeutic regimen using PMF, IVIG
and rituximab seems effective in treating the se-
vere AHR14. Not only was a significant reduction
in the anti-donor antibodies levels observed, but
also a complete return to normal of the histo-
logical findings on graft biopsy.
As in all these three patients, a higher histori-
cal and pretransplant sensitization or a previous
failed allograft are known risk factors for AHR,
suggesting that a humoral response against do-
nor-specific antigens plays a role in the
pathogenesis of this type of rejection1.
Although the considered triple regimen
showed a good effect in the acute severe set-
ting, its long-term effect has to be validated.
Moreover, with such an intensive immunosup-
pressive regimen, the infectious complications
have become the major potential problem.
Recommendations published in 200414 con-
cluded that effective treatment exists to reverse
post transplant AHR. While high IVIG pulses
(1-2g/kg) or plasmapheresis plus low dose IVIG
modalities have proven efficacy for antibody re-
moval14, they have yet to be tested in rigorous
prospective, multicentre studies. Rituximab or
splenectomy was also reported to increase the
treatment potency in the more severe cases14.
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In conclusion, although the diagnosis of se-
vere AHR requiring dialysis in patients already
under ATG is usually associated with renal graft
loss, it is possible to obtain complete histologi-
cal recovery, and clinical improvement, by em-
ploying triple therapy with PMF, IVIG and
Rituximab.  Prompt diagnosis and treatment is
essential for such a result.
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